MCM
UBX

MAI Capital Management’s Unity Biotechnology UBX Stock Holding History

MAI Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$39 – 4125
2025
Q2 		$39 Hold
100
– – ﹤0.01% 3920
2025
Q1 		$104 Hold
100
– – ﹤0.01% 3351
2024
Q4 		$98 Buy
+100
New +$124 ﹤0.01% 3427

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

MAI Capital Management's UBX Position: Q3 2025 in Review

MAI Capital Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 100 shares — an estimated $39 sold.

MAI Capital Management first reported a position in UBX in Q4 2024 and held it in 3 quarters. The position peaked at $104 in Q1 2025. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • MAI Capital Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • MAI Capital Management sold 100 Unity Biotechnology shares in Q3 2025, an estimated $39.
  • MAI Capital Management first reported a position in Unity Biotechnology in Q4 2024 and held it in 3 quarters.
  • MAI Capital Management's Unity Biotechnology position peaked at $104 in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on MAI Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.